Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Minini

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Lipidology|April 11, 2017
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemiaJohn J P Kastelein, G Kees Hovingh, Gisle Langslet, et al.
Molecular Genetics and Metabolism|June 13, 2024
Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidosesJulie Kissell, Camille Rochmann, Pascal Minini, et al.
Atherosclerosis|June 30, 2019
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trialsKausik K Ray, Antonio J Vallejo-Vaz, Henry N Ginsberg, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 18, 2025
Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trialsCynthia J Tifft, Isabela Batsu, Roberto Giugliani, et al.
Brain : a Journal of Neurology|October 18, 2022
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trialRaphael Schiffmann, Timothy M Cox, Jean-François Dedieu, et al.
Kidney Medicine|October 7, 2022
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKDRonald D Perrone, Ali Hariri, Pascal Minini, et al.
The Lancet. Neurology|July 21, 2023
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trialNir Giladi, Roy N Alcalay, Gary Cutter, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 19, 2022
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical TrialRonald T Gansevoort, Ali Hariri, Pascal Minini, et al.
Journal of Parkinson'S Disease|December 13, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD TrialM Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.
JAMA|September 3, 2013
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trialPhilippe Gabriel Steg, Shamir R Mehta, Charles V Pollack, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Lipidology|April 11, 2017
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemiaJohn J P Kastelein, G Kees Hovingh, Gisle Langslet, et al.
Molecular Genetics and Metabolism|June 13, 2024
Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidosesJulie Kissell, Camille Rochmann, Pascal Minini, et al.
Atherosclerosis|June 30, 2019
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trialsKausik K Ray, Antonio J Vallejo-Vaz, Henry N Ginsberg, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 18, 2025
Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trialsCynthia J Tifft, Isabela Batsu, Roberto Giugliani, et al.
Brain : a Journal of Neurology|October 18, 2022
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trialRaphael Schiffmann, Timothy M Cox, Jean-François Dedieu, et al.
Kidney Medicine|October 7, 2022
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKDRonald D Perrone, Ali Hariri, Pascal Minini, et al.
The Lancet. Neurology|July 21, 2023
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trialNir Giladi, Roy N Alcalay, Gary Cutter, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 19, 2022
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical TrialRonald T Gansevoort, Ali Hariri, Pascal Minini, et al.
Journal of Parkinson'S Disease|December 13, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD TrialM Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.
JAMA|September 3, 2013
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trialPhilippe Gabriel Steg, Shamir R Mehta, Charles V Pollack, et al.
Pageof 2